Cited by 773PI3K/AKT/mTOR signaling in cancerMetabolism, Diabetes, and CancerAdvanced Breast Cancer Therapies

The DOI matches its Crossref record; 129 of the 131 references it cites were found in a registry or an index.

Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway

Polivka, Jiri, Janku, Filip·2014·Pharmacology & Therapeutics

DOI 10.1016/j.pharmthera.2013.12.004

Open this paper in CoChat — free account

Abstract

Aberrations in various cellular signaling pathways are instrumental in regulating cellular metabolism, tumor development, growth, proliferation, metastasis and cytoskeletal reorganization. The fundamental cellular signaling cascade involved in these processes, the phosphatidylinositol 3-kinase/protein kinase-B/mammalian target of rapamycin (PI3K/AKT/mTOR), closely related to the mitogen-activated protein kinase (MAPK) pathway, is a crucial and intensively explored intracellular signaling pathway in tumorigenesis. Various activating mutations in oncogenes together with the inactivation of tumor suppressor genes are found in diverse malignancies across almost all members of the pathway. Substantial progress in uncovering PI3K/AKT/mTOR alterations and their roles in tumorigenesis has enabled the development of novel targeted molecules with potential for developing efficacious anticancer treatment. Two approved anticancer drugs, everolimus and temsirolimus, exemplify targeted inhibition of PI3K/AKT/mTOR in the clinic and many others are in preclinical development as well as being tested in early clinical trials for many different types of cancer. This review focuses on targeted PI3K/AKT/mTOR signaling from the perspective of novel molecular targets for cancer therapy found in key pathway members and their corresponding experimental therapeutic agents. Various aberrant prognostic and predictive biomarkers are also discussed and examples are given. Novel approaches to PI3K/AKT/mTOR pathway inhibition together with a better understanding of prognostic and predictive markers have the potential to significantly improve the future care of cancer patients in the current era of personalized cancer medicine.

Integrity signals

Registry

Crossref · 10.1016/j.pharmthera.2013.12.004

Cites

129 of 129 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621
PTEN , a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
AMPK: a nutrient and energy sensor that maintains energy homeostasis
Hardie, D. G., Ross, F. A., & Hawley, S. A. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3311 · Cited by 4,602
Cellular survival: a play in three Akts
Datta, S. R., Brunet, A., & Greenberg, M. E. (1999) · Genes & Development · doi:10.1101/gad.13.22.2905 · Cited by 4,216
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G. R., Carducci, M. A., Tomczak, P., Dutcher, J. P., Figlin, R. A., Kapoor, A., Starosławska, E., Sosman, J. A., McDermott, D. F., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,645
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A. F., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,448
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330
The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate
Maehama, T., & Dixon, J. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.22.13375 · Cited by 3,104
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61039-9 · Cited by 3,019
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
Yao, J. C., Shah, M. H., Ito, T., Lombard‐Bohas, C., Wolin, E. M., Cutsem, E. V., Hobday, T. J., Okusaka, T., Capdevila, J., de Vries, E. G. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009290 · Cited by 2,879

Show all 131 references

Research works printed but not linked: 1

Janku, 2011, Loss of PTEN expression in patients treated with PI3K/AKT/mTOR signaling pathway inhibitors, Cancer Res, 71

Sorted by citations

Items 701–773 of 773

Ginsenoside Rg1-Notoginsenoside R1-Protocatechuic aldehyde attenuates low shear stress-induced vascular endothelial cell dysfunctionPreprint
Zhang, L., Li, Y., Ma, X., Wang, X., Zhang, L., Li, Y., & Yang, W. (2020) · doi:10.21203/rs.3.rs-25782/v1 · Cited by 1
GPER‐mediated regulation of nuclear Akt/FOXO3a signaling (795.1)
Zekas, E., & Prossnitz, E. (2014) · The FASEB Journal · doi:10.1096/fasebj.28.1_supplement.795.1
Visual detection of Akt mRNA in living cell using gold nanoparticle beacon
Ma, Y., Tian, C., Li, S., Wang, Z., & Gu, Y. (2014) · Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE · doi:10.1117/12.2068691
Activation of PI3K by Thyroid Hormone Nuclear Receptors
Park, J. W., & Cheng, S.-Y. (2015) · Springer eBooks · doi:10.1007/978-3-319-20098-9_5
Molecular Biology Basics in the “Omics” Era: Cancer Pathology
Surve, D., & Idowu, M. O. (2015) · Springer eBooks · doi:10.1007/978-3-319-16304-8_2
Comparison of genes of JAK-STAT and PI3K-AKT cycles between cattle and pig in mammary gland
Rastgoo, S., & Nasab, M. P. E. (2014) · DergiPark (Istanbul University)
The AKT-mTOR Signaling Pathway for Drug Response Prediction and Prognostic Signatures
Moran, J. C., Baldelli, E., Petricoin, E. F., & Pierobon, M. (2016) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-34211-5_4
Small-Molecule Regulators of Autophagy as Potential Anti-cancer Therapy
Li, Q., Zhou, M., & Wang, R. (2016) · Current cancer research · doi:10.1007/978-3-319-42740-9_3
Examining the ligand-induced change in cell adhesion using the quartz crystal microbalance with dissipation monitoring
Garcia, M. D. P., Schweitzer‐Stenner, R., & Xi, J. (2014) · doi:10.17918/etd-6023
mTOR Silencing in Parkinson's Disease both in vitro and in vivo
Salama, M. (2015) · Brain Disorders & Therapy · doi:10.4172/2168-975x.1000167
Glimpses of the near future: a new generation of mTOR inhibitors
Nikitakis, N. G. (2016) · Oral Diseases · doi:10.1111/odi.12607
Vías de señalización celular y su aplicación
Luca, D. A. D. (2015)
Cancer After Kidney Transplantation
Snanoudj, R., Dantal, J., Lebbé, C., & Legendre, C. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801734-0.00037-0
Molecular Target Therapy against Neuroblastoma
Toyoda, H., Xu, D., Qi, L., & Hirayama, M. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.81706
IQGAP1 Scaffolds EGFR Interactions with Downstream Kinases
Lindberg, S. K. (2019) · Digital WPI
Expression of PI3K/AKT Signaling Pathway in IFN-β-induced Differentiation of Human Mesenchymal Stem Cells into Chondroblasts
Zhang, L., Huang, Z., Yan, W., & Li, Q. (2019) · International Journal of Sciences · doi:10.18483/ijsci.2156
US FDA‐Approved Small‐Molecule Kinase Inhibitors for Cancer Therapy
Yu, M., Tadesse, S., & Wang, S. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc214.pub2
PSMA-Targeting Redox Hyperbranched Poly (Amido Amine)-Mediated miR-133a-3p Delivery to Inhibit Bone Metastasis of Prostate CancerPreprint
Ye, Y., Zhang, L., Dai, Y., Wang, Z., Li, C., Peng, Y., Ma, D., & He, P. (2020) · doi:10.21203/rs.3.rs-36954/v1
Epidemiology of oral cancer and its relationship with inflammation
Bunai, K. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-88526-3.00001-4
The Construction and Analysis of ceRNA Network in H pylori infection atrophic gastritisPreprint
Bai, W.-J., Liang, J., & Wang, X. (2021) · Research Square · doi:10.21203/rs.3.rs-1047498/v1
NPR3 Inhibits EMT and Tumour Metastasis of Human Osteosarcoma by Activating AKT/mTOR-Mediated AutophagyPreprint
Yao, Z., Yang, Y., Chen, J., Chen, T., Han, L., Li, D., Ye, L., Zhu, Y., Feng, Y., Wu, J., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-923877/v1
AXL/GAS6 Inhibition Induces Apoptosis and Suppresses Cell Proliferation and Migration by Blocking the PI3K/AKT Signaling Pathways in Thyroid Cancer Cells in VivoPreprint
Zhang, Z., Su, Z., & Zhang, J. (2022) · Research Square · doi:10.21203/rs.3.rs-966855/v1
Up-regulation of nPKC Contributes to Proliferation of Pulmonary Artery Smooth Muscle Cells in Hypoxia-induced Pulmonary HypertensionPreprint
Shi, Y., Jiang, R., Qin, X., Gao, A., Hou, X., Chen, L., Xu, X., Chai, L., Guo, Y., Zhao, L., et al. (2020) · doi:10.21203/rs.3.rs-135752/v1
Faculty Opinions recommendation of PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer.
Plaxe, S. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.730367783.793560794
the inhibitory effect of Orexin system on different diseases through mTOR signaling pathwayPreprint
Song, Y., wang, B., wang, W., Shi, Q., & Fan, X.-L. (2022) · doi:10.22541/au.166698008.84814126/v1
Exploratory Clinical Development: From First in Humans to Phase 3 Ready
DiMartino, J. F. (2022) · Pediatric oncology · doi:10.1007/978-3-031-06357-2_5
Loss of liver kinase B1 in human seminoma
Kumar, M., Sahoo, S. S., Jamaluddin, M. F. B., & Tanwar, P. S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1081110
Describing mechanisms supporting macrophage-promoted escape of PTEN-deficient prostate cancer cells to understand disease recurrence
McCusker, S. (2023) · Queensland University of Technology · doi:10.5204/thesis.eprints.240009
Molecular genetics of soft tissue tumors
Lasota, J. P. (2016) · Cambridge University Press eBooks · doi:10.1017/9781107707504.006
Active compounds of Caodoukou () inhibit the migration, invasion and metastasis of human pancreatic cancer cells by targeting phosphoinosmde-3-kinase/ protein kinase B/mammalian target of rapamycin pathway.
Xiaohui, Y., Wang, J., Cheng, L., Yuxi, Z., Jianlin, H., & Minghua, L. (2023) · PubMed Central · doi:10.19852/j.cnki.jtcm.20230802.004
Cuproptosis-Related lncRNA Prognostic Profile, Immune microenvironment, Response and Immune-related gene prognostic index in LUADPreprint
sun, S., & Zhong, D. (2023) · Research Square · doi:10.21203/rs.3.rs-3313594/v1
N, n-bis (5-ethyl-2-hydroxybenzyl) methylamine induces apoptosis of non-small cell lung cancer cells via c-myc protein degradation
Sriratanasak, N., Chanvorachote, P., & Luanpitpong, S. (2019) · doi:10.58837/chula.the.2019.428
STK214947, a novel indole alkaloids, inhibits HeLa and SK-HEP-1 cells survival and EMT process by blocking the Notch3 and Akt signals
Xu, Z., Yuan, Y., Liu, J., Li, C., Chen, K., Wang, F., & Li, G. (2024) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001568
A Narrative Review on Therapeutic Potential of Fisetin in Colorectal Cancer: Focusing on apoptosis and biochemical processesPreprint
Zamanian, M. Y., Taheri, N., Ramadan, M. F., Mohammed, J. S., Alkhayyat, S., Sergeevna, K. N., Alsaab, H. O., Hjazi, A. M., Vasei, F. M., & Daneshvar, S. (2024) · doi:10.22541/au.171703475.55936332/v1
Anticancer Therapeutics from Insect-derived Compounds
Jangir, S., & Nadumane, V. K. (2024) · Current Cancer Therapy Reviews · doi:10.2174/0115733947311327240802115914
Desmoplakin mutations in cardiac fibroblasts cause TGFβ1-mediated pathological fibrogenesis in desmoplakin cardiomyopathy via beclin-1 regulationPreprint
Wei, C., Chan, S. F., Saguner, A. M., Brunckhorst, C., Duru, F., Marine, J. E., James, C. A., Calkins, H. G., Judge, D. P., Shou, W., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.09.612149
Cancer signaling pathways: targets and treatment
Vishnusai, B., Sharma, R., Parihar, V. K., & Kumar, N. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95258-3.00006-0
NEDD4's effect on osteoblastogenesis potential of bone mesenchymal stem cells in rats concerned with PI3K/Akt pathway
Li, B., Zhang, S., Yun, X., Liu, C., Xiao, R., Lu, M., Xu, X., & Lin, F. (2024) · Differentiation · doi:10.1016/j.diff.2024.100830
Involvement of Mitogen-Activated Protein (MAP) Kinase Pathway in the Etiopathogenesis of Cancer and Its Role in Cancer Therapeutics
Nabi, N., Shafat, P. M., Bashir, S., & Khan, M. S. (2025) · Springer eBooks · doi:10.1007/978-981-96-2763-9_2
A Combined Multi-Omics and Supervised Learning Strategy Uncovers an Epithelial Signature of Radiotherapy Response in Colorectal CancerPreprint
Kumar, R., He, Y., Zhou, J., Beggs, A. D., & Gendoo, D. M. A. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.10.648131
DDTC-Cu(I) inhibits human osteosarcoma cells growth by repressing MET/PI3K/AKT signaling pathway
Zhou, R., Yan, L., Zhang, K., Chen, S., Yang, Y. P., Wei, X., Pan, Y., Xu, C., Sun, X., Lv, Z., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-06748-6
Additional file 1 of TMED3 promotes the development of malignant melanoma by targeting CDCA8 and regulating PI3K/Akt pathway
Guo, X., Yin, X., Xu, Y., Li, L., Yuan, M., Zhao, H., Jiang, Y., Shi, X., Bi, H., Liu, Y., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22619912
Additional file 6 of A pyroptosis-related gene signature provides an alternative for predicting the prognosis of patients with hepatocellular carcinoma
Lin, D., Chen, Z., Zeng, Y., Ding, Y., Zhao, L., Xu, Q., Yu, F., Song, X., & Zhu, X. (2023) · Figshare · doi:10.6084/m9.figshare.22605050
Additional file 1 of A pyroptosis-related gene signature provides an alternative for predicting the prognosis of patients with hepatocellular carcinoma
Lin, D., Chen, Z., Zeng, Y., Ding, Y., Zhao, L., Xu, Q., Yu, F., Song, X., & Zhu, X. (2023) · Figshare · doi:10.6084/m9.figshare.22605035
Additional file 4 of A pyroptosis-related gene signature provides an alternative for predicting the prognosis of patients with hepatocellular carcinoma
Lin, D., Chen, Z., Zeng, Y., Ding, Y., Zhao, L., Xu, Q., Yu, F., Song, X., & Zhu, X. (2023) · Figshare · doi:10.6084/m9.figshare.22605044
Additional file 5 of A pyroptosis-related gene signature provides an alternative for predicting the prognosis of patients with hepatocellular carcinoma
Lin, D., Chen, Z., Zeng, Y., Ding, Y., Zhao, L., Xu, Q., Yu, F., Song, X., & Zhu, X. (2023) · Figshare · doi:10.6084/m9.figshare.22605047
Additional file 2 of A pyroptosis-related gene signature provides an alternative for predicting the prognosis of patients with hepatocellular carcinoma
Lin, D., Chen, Z., Zeng, Y., Ding, Y., Zhao, L., Xu, Q., Yu, F., Song, X., & Zhu, X. (2023) · Figshare · doi:10.6084/m9.figshare.22605038
Additional file 3 of A pyroptosis-related gene signature provides an alternative for predicting the prognosis of patients with hepatocellular carcinoma
Lin, D., Chen, Z., Zeng, Y., Ding, Y., Zhao, L., Xu, Q., Yu, F., Song, X., & Zhu, X. (2023) · Figshare · doi:10.6084/m9.figshare.22605041
Bladder cancer: PI3K/Akt/mTOR signaling dysregulation, potential proteomic techniques, therapeutic strategies, and future perspectives
Jan, I., Ali, T., Bashir, R., Khaki, P. S. S., Andrabi, K. I., & Bader, G. N. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-23908-3.00018-6
Research Progress on the Interaction between Renal Cancer and the Tumor Microenvironment and Its Potential Therapeutic Strategies
桂, 佳. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.162701
RHBDD1 promotes cervical cancer progression by activating the EGFR/PI3K/AKT signaling pathway
Li, W., Liang, X., Wu, X., Zheng, B., & Cheng, J. (2026) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2026.110777
Cystathionine‐γ‐Lyase/Hydrogen Sulfide Axis Plays a Crucial Role in Promoting the Progression of Cervical Cancer
Wang, J., Zhang, Y. W., Wang, H., Zhang, J., Jiang, Q., & Wu, D. (2026) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.70765
Rôle de la kinase Akt dans la chimiorésistance : Régulation de l’équilibre Apoptose-Sénescence
Vétillard, A. (2015) · theses.fr (ABES) · doi:10.70675/d0db61dazb197z42dczbb98z6f0276f570b6
The molecular pathogenesis of Epstein–Barr virus-associated B-cell lymphoproliferative disorders: a scoping review
Vets, J., Haest, X., & Tousseyn, T. (2026) · Expert Review of Hematology · doi:10.1080/17474086.2026.2655963
Role of PTEN during collective cell migration
Capuana, L. (2019) · theses.fr (ABES) · doi:10.70675/33db0f4fz4744z4b1az8f56zbdb5261cb77b
Factors that contribute to B cell oncogenesis in people living with HIV
Shmakova, A. (2023) · theses.fr (ABES) · doi:10.70675/1d51b9d6z9a12z41f9z8f98z0c7f955aeb54
Discovery of 1H-pyrazolo[3,4-d]pyrimidin-4-ylamine derivatives as potent PI3Kδ/BTK dual-target inhibitors for the treatment of B-cell lymphoma
Wang, Z., Ye, Y., Kang, Y., Zheng, H., Chang, X., Xu, X., Zhang, C., & Huang, W. (2026) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2026.118660
γ-Tocotrienol inhibits HeLa cell proliferation likely via modulation of the PI3K/AKT/mTOR signaling pathway
Tian, Y., Wang, X., Zhaoxin, L., Mi, Y., Zhou, S., & Xu, W. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1804277
Efficacy and Safety of Everolimus in Advanced Unresectable and Progressive Epithelioid Hemangioendothelioma: A Single-Center Case Series
Tan, H., Wang, H., Sun, Y., Ying, J., & Chi, Y. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s553262
Basic Clinical Bidirectional Empowerment: Synergistic Breakthrough in Molecular Mechanisms and Clinical Management of Small Cell Cervical Carcinoma
Huang, M., & Li, S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27156783
Desmoplakin Mutations in Cardiac Fibroblasts Cause TGFβ1-Mediated Pathological Fibrogenesis in Desmoplakin Cardiomyopathy Via Beclin-1 Regulation
Wei, C., Chan, S. F., Saguner, A. M., Brunckhorst, C., Duru, F., Marine, J. E., James, C. A., Calkins, H. G., Judge, D. P., Shou, W., et al. (2026) · Circulation Research · doi:10.1161/circresaha.124.325512
Emetine and Its Derivatives as Anticancer Agents Targeting the PI3K / AKT / mTOR Pathway: A Narrative Review of Mechanisms, Pharmacology, and Clinical Insights
Khatun, M. I., Selim, S., Malik, A. H., Hasan, M. S. A., Khalipha, A. B. R., Yana, N. T., Alshahrani, M. Y., Hossain, M. A., Rakib, I. H., Chakrabarty, A., et al. (2026) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.71328
HOXC9 promotes cell proliferation and suppresses mitochondria-dependent apoptosis through the AKT/mTOR pathway in esophageal squamous cell carcinoma
Yu, X., Wang, Y., Ju, X., Li, Z., Song, J., Wu, B., Ding, Q., Jiang, Y., & Wu, Y. (2026) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-026-05715-7
Arsenic-endemic regions correlate with elevated tumor mutational burden and genomic alterations in urothelial carcinoma
Kuo, J.-H., Hsu, S.-Y., Tung, H.-T., Ou, Y., Tsai, H.-T., Tzai, T., Cha, T., Chang, K., & Tsai, Y. (2026) · Urological Science · doi:10.1097/us9.0000000000000133
RHEB-CSF1R signaling, autophagy, and metastatic plasticity in pancreatic cancer: Current advances, controversies, and translational opportunities
Hu, J.-X., Zhang, Y., Chen, Y.-M., & Cao, L. (2026) · World Journal of Gastroenterology · doi:10.3748/wjg.v32.i43.119315
BindingDB Entry 50002326: Discovery of a Novel Series of 7-Azaindole Scaffold Derivatives as PI3K Inhibitors with Potent Activity.
BindingDB (2020) · UC San Diego · doi:10.7270/q2cr5wzt
BindingDB Entry 50015475: Design, Synthesis, and Evaluation of Potent, Selective, and Bioavailable AKT Kinase Degraders.
BindingDB (2023) · UC San Diego · doi:10.7270/q2dz0d73
BindingDB Entry 50006296: Identification and optimisation of a 4',5-bisthiazole series of selective phosphatidylinositol-3 kinase alpha inhibitors.
BindingDB (2020) · UC San Diego · doi:10.7270/q2w098xh
BindingDB Entry 50015996: Discovery of 2-Methyl-2-(4-(2-methyl-8-(1
BindingDB (2023) · UC San Diego · doi:10.7270/q22r3wn7
BindingDB Entry 50046461: Discovery of a novel tricyclic 4H-thiazolo[5',4':4,5]pyrano[2,3-c]pyridine-2-amino scaffold and its application in a PI3Ka inhibitor with high PI3K isoform selectivity and potent cellular activity.
BindingDB (2016) · UC San Diego · doi:10.7270/q2g73gjg
BindingDB Entry 50046446: Identification and optimisation of 4,5-dihydrobenzo[1,2-d:3,4-d]bisthiazole and 4,5-dihydrothiazolo[4,5-h]quinazoline series of selective phosphatidylinositol-3 kinase alpha inhibitors.
BindingDB (2016) · UC San Diego · doi:10.7270/q2df6sz5
BindingDB Entry 50002306: Design, synthesis, and biological evaluation of novel 3-substituted imidazo[1,2-a]pyridine and quinazolin-4(3H)-one derivatives as PI3Kα inhibitors.
BindingDB (2020) · UC San Diego · doi:10.7270/q2kh0qxv
BindingDB Entry 50007837: Design, synthesis and pharmacological evaluation of a novel mTOR-targeted anti-EV71 agent.
BindingDB (2021) · UC San Diego · doi:10.7270/q23j3hbw

Authors: Polivka, J., & Janku, F.
Venue: Pharmacology & Therapeutics
Publisher: Elsevier BV
Published: 2014-05
Volume: 142
Issue: 2
Pages: 164-175
ISSN: 0163-7258 (ISSN-L)
DOI: 10.1016/j.pharmthera.2013.12.004
OpenAlex: W2132052921
Cited by: 765
References: 131
Citations by year: 2026: 20 · 2025: 31 · 2024: 41 · 2023: 71 · 2022: 56 · 2021: 90 · 2020: 80 · 2019: 103 · 2018: 63 · 2017: 71 · 2016: 51 · 2015: 59 · 2014: 28
FWCI: 4.39
Type: journal article
Language: en
Open access: closed
Locations: Pharmacology & Therapeutics (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
Keywords: PI3K/AKT/mTOR pathway, targeted cancer therapy, molecular targets, PI3K inhibitors, mTOR inhibitors, everolimus, temsirolimus, MAPK signaling, oncogenic mutations, tumor suppressor, prognostic factors, predictive biomarkers, precision oncology, carcinogenesis
MeSH terms: Phosphoinositide-3 Kinase Inhibitors, Animals, Antineoplastic Agents, Humans, Neoplasms, Drug Design, Signal Transduction, Protein Kinase Inhibitors, Proto-Oncogene Proteins c-akt, Phosphatidylinositol 3-Kinase, TOR Serine-Threonine Kinases, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks